The global zeposia market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Zeposia is a treatment for relapsing forms of multiple sclerosis, which includes clinically isolated syndrome, relapsing syndrome, and a second progressive disease, in adults. The active ingredient in Zeposia, ozanimod, inhibits the activity of sphingosine-1-phosphate receptors in lymphocytes (immune cells that can attack the tissue in diseases such as multiple sclerosis or ulcerative colitis). By adhering to these receptors, ozanimod blocks the lymphocytes from moving from the lymph nodes to the brain, spinal cord, or intestines, thus reducing the damage it causes to multiple sclerosis and ulcerative colitis.
Zeposia is effective in reducing the rate of relapse in two main studies involving a total of 2,666 patients with RRMS. In the first study lasting more than one year, the mean rate of annual relapse in patients treated with standard Zeposia dose was almost half that in patients treated with another drug, interferon beta-1a (0.18 compared to 0.35 times). In the second study, which lasted two years, patients treated with the usual dose of Zeposia had a mean frequency of 0.17 per year, compared with 0.28 in patients given interferon beta-1a.
Some major players in the market include Bristol-Myers Squibb. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.
In May 2020, European Commission has granted Zeposia (ozanimod) Marketing Authorization for the treatment of adults with moderate to severe ulcerative colitis (UC) who have not adequately responded to, lost response, or tolerated routine treatment or biological agents. Zeposia, an oral medication taken once a day, is a module for receiving sphingosine 1-phosphate binding to high consistency selectively for S1P subtypes 1 (S1P1) and 5 (S1P5). Zeposia is the first and only S1P oral module approved by the UC and represents a new way to treat this incurable immune system.
(Get 15% Discount on Buying this Report)
Get Sample Copy of zeposia market at:
https://orionmarketreports.com/request-sample/?id=95591&submit=Request+Sample%0D%0A
Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Type
By Application
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
Top major key players:
Bristol-Myers Squibb, among others.
Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?
A full report of zeposia market is available at:
https://orionmarketreports.com/global-zeposia-market/95591/
Global Zeposia Market Report by Segment
By Type
7 Capsules/Box
30 Capsules/Box
By Application
Retail Pharmacy
Hospital Pharmacy
Other
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
